News

AddToAny

Google+ Facebook Twitter Twitter

Biomarker for bladder cancer

A new diagnostic technique has revealed a protein biomarker that accurately differentiates bladder cancer from benign inflammation.

p10-13-news-neutrophil-white_blood_cell-science-photo-library-f0224299.jpg

Label-free digital pathology using infrared imaging, with subsequent proteomic analysis, was used to discover the first protein biomarker (AHNAK2) for bladder cancer.

AHNAK2 differentiates between chronic cystitis (inflammation of the bladder) and a non-muscle invasive-type BC (carcinoma in situ), which is challenging to diagnose.

A new report describes this diagnostic procedure, which is label-free, automated, observer-independent, and as sensitive and specific as established histopathological methods.  

Image credit | Science Photo Library 

Related Articles

"Disasters lead to reductions in cancer screening"

Cervical cancer screening rates in Japan were significantly affected in the years following the devastating Great East Japan Earthquake of 2011.

Cervical screening in Moldova

Lead Biomedical Scientist and British Association for Cytopathology Executive Committee Member Hedley Glencross introduces a project to improve the outdated cervical screening programme in the Republic of Moldova.

Breakthrough for the leading cause of blindness

Professor Simon Clark discusses how his international team of scientists identified a protein that is strongly linked to the most common cause of blindness in developed countries.

IBMS President inaugurated

Allan Wilson has been inaugurated as the new President of the IBMS.

Top